BASF steps up contract manufacturing activities
BASF plans to step up its activities in the area of contract manufacturing - the exclusive production of active ingredients and advanced intermediates for the pharmaceutical industry. More and more pharmaceutical companies are concentrating on research and development as well as on the marketing of new products. As a result, the production of active ingredients is increasingly being contracted out to fine chemical companies that both specialize in the synthesis of complex molecules and have suitable multipurpose plants that meet the pharmaceutical industry's standards.
BASF is a leading company in the area of fine chemicals and is already an important supplier to the pharmaceutical industry. It generates sales of more than €500 million per year with active ingredients and excipients (e.g. ibuprofen and substances used in the tableting process such as Kollidon®) as well as intermediates (e.g. ChiProsTM).
"Our expertise in organic chemistry and process development together with the experience in the manufacture of active ingredients that we have gathered over the past 30 years are a good basis for building partnerships with the pharmaceutical industry," says Gabriel Tanbourgi, Group Vice President Strategic Marketing Pharma Solutions at BASF.
BASF has a comprehensive portfolio of standard and differentiation technologies in organic synthesis as well as broad experience in the development of chemical processes. Both are tailored to the needs of the pharmaceutical industry. At its sites in Ludwigshafen and Minden, Germany, BASF operates FDA-audited (Federal Drug Administration) production facilities in which kilogram to metric ton quantities of active ingredients are manufactured in accordance with GMP (Good Manufacturing Practices).
Growth in the custom manufacturing market for the world's pharmaceutical market is estimated at 8 percent per year. BASF plans to become one of the leading competitors in this business.
Topics
Organizations
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.

Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
Last viewed contents
Analysis Of The European Miniature and Sub-Miniature Pneumatic Components Market
Oxea Announces Price Increases for Intermediates

Watching single protons moving at water-solid interfaces - A major experimental breakthrough
